

23 October 2015 EMA/38687/2015 Press Office

## Guidelines and concept papers

Adopted during the CHMP meeting 19-22 October 2015

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under <a href="Regulatory/Human/Scientific guidelines">Regulatory/Human/Scientific guidelines</a>. Documents for public consultation will also be available under <a href="Document search/Public consultations">Document search/Public consultations</a>.

#### **Safety Working Party**

Reference number	Document	Status
EMA/CHMP/SWP/272921/20 12	Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use	Adopted
EMA/CHMP/SWP/2145/2000 Rev. 1	Guideline on Non-Clinical Local Tolerance Testing of Medicinal Products	Adopted
EMA/CHMP/SWP/333948/20 15	Concept paper on a Proposal to limit the applicability of the CPMP/CVMP Note for Guidance on Limitations to the Use of Ethylene Oxide in the Manufacture of Medicinal Products (CPMP/QWP/159/01) to veterinary medicinal products	Adopted

### **Quality Working Party**

Reference number	Document	Status
EMA/CHMP/QWP/128067/20 14	Question and answer on expression/declaration of potency in quantitative and qualitative composition for Vancomycin products	Adopted



#### **Committees**

Reference number	Document	Status
EMA/CHMP/261500/2014	Scientific guidance on post- authorisation efficacy studies	Adopted for 3-months public consultation
EMA/CHMP/57760/2015	Reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME)	Adopted for 2-months public consultation

# Cardiovascular Working Party

Reference number	Document	Status
EMA/CHMP/41252/2015	Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients	Adopted for 6-months public consultation

## **Asthma Guideline Drafting Group**

Reference number	Document	Status
CHMP/EWP/2922/01 Rev. 1	Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Asthma	Adopted